Cart
sales@molnova.com
Erastin2
CAS No. 1695533-44-8
Erastin2( —— )
Catalog No. M34807 CAS No. 1695533-44-8
Erastin2 is a ferroptosis inducer and inhibitor of the system xc- cystine/glutamate transporter.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 223 | In Stock |
|
| 5MG | 155 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 395 | In Stock |
|
| 50MG | 504 | In Stock |
|
| 100MG | 641 | In Stock |
|
| 200MG | 907 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameErastin2
-
NoteResearch use only, not for human use.
-
Brief DescriptionErastin2 is a ferroptosis inducer and inhibitor of the system xc- cystine/glutamate transporter.
-
DescriptionErastin2 is a ferroptosis inducer and a potent, selective inhibitor of the system xc(-) cystine/glutamate transporter.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetFerroptosis
-
RecptorFerroptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1695533-44-8
-
Formula Weight623.14
-
Molecular FormulaC36H35ClN4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (160.48 mM; Ultrasonic )
-
SMILESCC(C)Oc1ccc(cc1-n1c(CN2CCN(CC2)C(=O)COc2ccc(Cl)cc2)nc2ccccc2c1=O)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cao JY, et al. A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity. Cell Rep. 2019 Feb 5;26(6):1544-1556.e8. ?
molnova catalog
related products
-
BCP-T.A
BCP-T.A is an ferroptosis inducer that acts by binding to GPX4.
-
FINO2
FINO2 is a potent ferroptosis-inducing compound that inhibits GPX4 activity. It functions as a stable oxidant, effectively oxidizing ferrous iron and demonstrating stability across varying pH levels.
-
MMRi62
MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53).
